Cancer Management and Research (Sep 2021)
Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer
Abstract
Davide Franceschini,1 Maria Ausilia Teriaca,1 Luca Dominici,1 Ciro Franzese,1,2 Marta Scorsetti1,2 1Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Milan, Italy; 2Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence: Maria Ausilia TeriacaDepartment of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, via Manzoni 56, Rozzano, Milan, 20089, ItalyTel +39 0282247461Email [email protected]: Oligometastatic patients are a heterogeneous and yet not well-defined population. The actual definition identifies as oligometastatic, patients with 1– 5 metastases in 1– 3 different organs. However, only a proportion of these patients are “true” oligometastatic and therefore derive some kinds of benefit from local ablative approaches like stereotactic ablative radiation therapy (SABR). Since SABR is an easily accessible, effective and well-tolerated treatment, it is widely employed in the oligometastatic scenarios, without a particular focus on selection criteria. However, it should be crucial to identify predictive and prognostic features that could be clinically implemented. Therefore, we conducted this narrative review of the available literature to summarize all clinical, radiomic, genetic and epigenetic features found to be predictive of overall survival, progression-free survival or local control of oligometastatic patients treated with SABR.Keywords: stereotactic ablative radiation therapy, oligometastases, prognostic factors, selection criteria
